Pharma BD Deal Intelligence

ProMIS Neurosciences Inc. / Ossianix, Inc.

2026 · Licensing/Option · Complete

ProMIS Neurosciences Inc. (Nasdaq: PMN) licensed TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1), from privately held Ossianix, Inc. TXP1 is built on a deimmunized single-domain VNAR antibody scaffold significantly smaller than a conventional antibody. The agreement grants ProMIS rights to use TXP1 with PMN310, its lead humanized IgG1 antibody for Alzheimer's disease that selectively targets toxic oligomers while avoiding plaque and is in the Phase 1b PRECISE-AD study (NCT06750432) under FDA Fast Track, plus options to apply the technology to its Parkinson's disease (PMN442, alpha-synuclein) and ALS (PMN267, TDP-43) programs. Ossianix receives an undisclosed upfront payment plus development, regulatory and commercial milestones and royalties on global net sales. Ossianix previously reported that TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold, including in non-human primate studies, with no accumulation observed in liver, spleen, lung, kidney, bone marrow, heart or muscle. ProMIS expects to fund short-term obligations from existing cash with no change to its cash runway through 2027. Destum Partners served as transaction advisor to Ossianix.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →